Literature DB >> 20653719

Expression of vimentin and high-molecular-weight cytokeratin (clone 34ßE12) in differentiating reactive renal tubular cells from low-grade urothelial carcinoma cells in voided urine.

H Ohsaki1, E Hirakawa, M Nakamura, Y Norimatsu, H Kiyomoto, R Haba.   

Abstract

OBJECTIVE: Reactive renal tubular cells show features of an atypical repair reaction. Differentiation between reactive renal tubular cells and low-grade urothelial carcinoma (LG-UC) cells can therefore be a diagnostic challenge based on morphology alone. In this study, we evaluated the diagnostic utility of vimentin and a high-molecular-weight cytokeratin antibody (clone 34ßE12) in differentiating reactive renal tubular cells from LG-UC.
METHODS: We evaluated voided urine cytology and surgical specimens from 40 patients with renal disease, and 17 patients with LG-UC. All slides were stained with vimentin and 34ßE12.
RESULTS: In the reactive renal tubular cells in voided urine cytology, vimentin showed strong cytoplasmic staining in 39/40 (97.5%) cases, but all were negative for 34ßE12. LG-UC cells showed positive staining for 34ßE12 in 3/17 (17.6%) cases, whereas none were positivity for vimentin. The reactive renal tubular cells of histological specimens in the renal disease group demonstrated positive for vimentin in all 40 cases and all were negative for 34ßE12. The LG-UC group showed abnormal staining for 34ßE12 in 4/17 (23.5%) cases, whereas none were positive for vimentin.
CONCLUSIONS: Vimentin expression in urine cytology can help to distinguish reactive renal tubular cells from LG-UC. However, 34ßE12 does not appear to be a useful adjunct to distinguish these two groups in voided urine cytology.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653719     DOI: 10.1111/j.1365-2303.2010.00791.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  5 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor.

Authors:  Bisong Zhu; Lin Qi; Sulai Liu; Wentao Liu; Zhenyu Ou; Minfeng Chen; Longfei Liu; Xiongbing Zu; Jun Wang; Yuan Li
Journal:  BMC Cancer       Date:  2017-02-06       Impact factor: 4.430

3.  Advanced primary urethral cancer: a case report.

Authors:  Huan Chen; Li Li Zou; Chuan Jiang Dong; Tao Li; Zi Qiang Dong
Journal:  J Med Case Rep       Date:  2019-11-29

4.  p53 expression in repair/reactive renal tubular cells: A potential pitfall leading to a false-positive diagnosis of urine cytology.

Authors:  Kaori Enomoto; Toru Matsunaga; Tadashi Sofue; Akihiro Nakamura; Eiichiro Hirakawa; Emi Ibuki; Reiji Haba; Shingo Kamoshida; Hiroyuki Ohsaki
Journal:  Cancer Med       Date:  2021-11-16       Impact factor: 4.452

Review 5.  Role of anti-vimentin antibodies in allograft rejection.

Authors:  Marlene L Rose
Journal:  Hum Immunol       Date:  2013-06-15       Impact factor: 2.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.